Apixaban + Warfarin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Antiphospholipid Syndrome
Conditions
Antiphospholipid Syndrome, Thrombosis
Trial Timeline
Dec 10, 2014 → Mar 1, 2022
NCT ID
NCT02295475About Apixaban + Warfarin
Apixaban + Warfarin is a approved stage product being developed by Bristol Myers Squibb for Antiphospholipid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02295475. Target conditions include Antiphospholipid Syndrome, Thrombosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02942407 | Approved | Completed |
| NCT02889562 | Phase 2/3 | Completed |
| NCT02450682 | Phase 2 | Withdrawn |
| NCT02283294 | Phase 3 | Completed |
| NCT02295475 | Approved | Completed |
Competing Products
4 competing products in Antiphospholipid Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RAY121 | Chugai Pharmaceutical | Phase 1 | 33 |
| RAY121 | Chugai Pharmaceutical | Phase 1 | 33 |
| Crovalimab + Placebo + VKA | Roche | Phase 2 | 52 |
| Rivaroxaban | Bayer | Approved | 82 |